Join collection
Hello, welcome to our official website!
2018亚洲旅游产业年会将于9月在上海召开
2019-01-12

  -中外行业大咖云集,共谋新文旅时代发展之道

  

  上海2018年8月2日电 /美通社/ -- 2018年9月14日,由中国**财经媒体《21世纪经济报道》,联合国内**旅游学府南开大学旅游与服务学院主办的“2018亚洲旅游产业年会”将在上海盛大举行。

  

  本届年会将以“文旅融合·亚洲机遇”为主题,聚焦产业发展和机遇的更深层次议题,关注文旅融合战略下亚洲及全球旅游产业合作发展的新方向、新机遇。  


2017亚洲旅游产业年会

  

  文旅融合加速产业升级,亚洲旅游进入新时代

  

  亚洲旅游产业发展到今天,尤其是随着中国经济结构向消费时代的全面转型、国家“一带一路”倡议推进和自由贸易政策的深化,已成为世界旅游市场发展的主导力量之一。作为聚集新兴发展国家*多的区域,亚洲服务业升级转型必将促进旅游产业的进一步国际化,为旅游产业带来全新的发展机遇。

  

  2018年,伴随国家体制改革向纵深发展,中国正在进入文化塑造与旅游体验相融合的新文旅时代,大型非旅资本正加速进军文旅产业,跨行业投资态势更趋明显。

  

  继成功打造两届亚洲旅游产业年会之后,作为商业报道***,《21世纪经济报道》将携手国内旅游专业顶尖学府南开大学旅游与服务学院,并在南方财经全媒体集团、现代旅游业发展协同创新中心等指导单位的大力支持下,再度推出2018亚洲旅游产业年会。

  

  本届年会包括“拥抱文旅融合的亚洲机遇”主论坛、旅游产业投资与创新高峰论坛、21世纪住宿业高峰论坛,以及2018旅游及住宿业资源推介、对接会等环节。会议将凝聚产业、资本、智库和政府间的多方共识和力量,共同探索各方在投资环境营造、旅游产业规划设计、旅游业态的培育打造、旅游市场的营销策划等合作领域的创新模式,为推进文化与旅游融合发展、促进亚洲经济共同繁荣做出积极贡献。

  

  中外行业大咖云集,共谋新文旅时代发展之道

  

  本届论坛主议题为“拥抱文旅融合的亚洲机遇”。在消费端,2017年中国旅游业对 GDP 的综合贡献为9.13万亿元,占 GDP 总量的11.04%;与此同时,全国规模以上文化及相关产业2017年实现营业收入9.2万亿元,比上年增长10.8%。两个超过9万亿、同样两位数的增长率,不仅证明文旅产业已经融入到我国千家万户的日常生活之中,而且预示着现在文化旅游产业正处于快速布局阶段和大发展的前夜,2018年**数据也证明了这一点,2017年全年中国旅游直接投资超过1.5万亿元,同比增长16%。其中全国已有144支旅游产业投资基金,总规模超过8000亿元。

  

  中国旅游研究院按季度开展的中国城镇和农村居民出游意愿调查数据显示,今年三季度居民总体旅游意愿高达86.4%。现代旅游业发展协同创新中心主任、国家旅游局中国旅游智库秘书长、南开大学教授石培华指出,中国入境旅游80%以上还是亚洲的区域市场,相互交融性更强,同时也是竞争性**的市场。他认为,旅游要想实现共赢,还是要在产业的深度合作上下文章,从大众的观光旅游和专项旅游,发展到融合健康、快乐、文化体验、教育的旅游业态。如何把握住这历史性机遇正是本届年会的聚焦所在。

  

  “掘金文化旅游大时代”是本届年会的另一个主要议题。2018年文旅产业一个鲜明的特点就是在万亿投资中,民间资本投资已经占比达到六成以上,文旅产业已形成民营、国有企业和政府投资共同参与的多元主体投资格局;在这样一个背景下,文旅产业与金融产业的结合已成为大势所趋。2018年一个值得关注的现象是,大型非旅资本正加速进军旅游业,跨行业投资态势更趋明显。比如在重庆近郊江津县,一个覆盖三个乡镇占地近20平方公里总投资超过百亿的乡村振兴加全域旅游项目正在悄然推进,投资者却是此前并未涉足文旅行业的鲁能集团。

  

  实际上,作为一年一度的盛会,2018亚洲旅游产业年会设置了近三十个主旨演讲和圆桌论坛话题,内容包括文化与旅游融合的中国样本、新文旅的投资逻辑、当旅游有了大 IP:文创产业发展机遇、赋能下的旅游项目投资运营之道及爆款IP酒店背后的商业模式探索等。

  

  而作为国内第一家全媒体财经集团所属21世纪经济报道,也充分发挥了媒体平台连接各方资源的优势,2018亚洲旅游产业年会将邀请来自文化和旅游部、联合国世界旅游组织、欧盟旅游委员会、澳大利亚、加拿大、韩国、香港、澳门等旅游局或者大使馆等官员;海南、西安、洛阳等省市地方政府代表;同时还将邀请华侨城集团、复星集团、默林集团、IDG、红杉资本、万达影视、华谊兄弟、长隆集团、华强方特、万豪国际集团、洲际酒店集团、开元酒店集团、携程等近百位行业**参加。

  

  同期活动精彩纷呈,资源对接会、行业颁奖同期举行

  

  论坛当天下午还特设“2018旅游及住宿业资源推介会”,主办方秉持“求真、务实、**”的原则,旨在搭建产业与资本对接的平台,帮助优秀的旅游开发项目、旅游创业项目寻找投资方,为具备资金实力和投资意向的企业及机构挖掘具有投资价值的旅游项目,从而助推旅游业的产融结合,为产业可持续发展贡献力量。


2017亚洲旅游“红珊瑚”奖颁奖典礼

  

  作为亚洲旅游产业年会系列活动之一,组委会还发起举办2018(第十五届)中国酒店“金枕头”奖评选和“亚洲旅游‘红珊瑚’奖”评选活动。“金枕头”奖评选将以大数据评价体系为主要依据,聆听酒店消费者真实声音,甄选**市场口碑和影响力的酒店集团、酒店品牌和单体酒店,发现中国酒店业转型升级中的榜样力量。“红珊瑚”奖评选通过大数据调研、互动投票以及专家评审的方式,对亚洲各旅游目的地、旅游项目、旅游服务商、旅游人物等产业链各方进行客观评价,旨在为大众提供更多旅游消费指引的同时,也帮助旅游产业经营者和管理者了解产业的状况和市场表现,推动亚洲旅游产业的健康发展。2018(第十五届)中国酒店“金枕头”奖和亚洲旅游“红珊瑚”奖的颁奖典礼将于年会当晚隆重举行。


暂无评论!
我要评论 只有购买过该商品的用户才能评论。

Gotham Therapeutics Establishes Advanced Oncology Profiling Cascade with ProQinase to Progress its Portfolio of Epitranscriptomic Drug CandidatesWEDNESDAY, OCTOBER 30, 2019Gotham Therapeutics, a biotechnology company developing a novel drug class targeting RNA-modifying proteins, and ProQinase, an early stage drug-discovery company, recently acquired by Malvern/PA-based Reaction Biology Corp., today announced that they have established an array of advanced biochemical and cellular assays to characterize epitranscriptomic-directed compounds.“Establishing tailored target engagement, cell biology, phenotypic, and in-vivo assays to evaluate compounds originating from our three most advanced epitranscriptomic programs in parallel is a crucial next step to develop our broad pipeline towards the clinic,” said Dr. Gerhard Müller, Chief Scientific Officer of Gotham Therapeutics. “By pursuing the full range of the reader-writer-eraser continuum, we are able to focus on targets with the most compelling links to disease and advance those programs in tandem.”“Combining our high proficiency in providing customized solutions as early stage drug-discovery services, including tailor-made biochemical and cell-based assays, with Gotham’s expertise in epitranscriptomics, we were able to establish in a very short time a set of customized enzymatic and cellular assays for compounds addressing three different mRNA-modifying targets,” said Dr. Sebastian Dempe, Chief Executive Officer of ProQinase. “We look forward to supporting Gotham as the company advances its programs into lead optimization and to continued work with the Gotham team assisting the company to advance its broad pipeline in a time-effective manner.”In addition to establishing a tailor-made profiling cascade for compounds from its three most advanced programs, Gotham has also made progress in strengthening its drug discovery engine and developing its candidate base. Gotham previously completed the gene-to-lead phase for its drug discovery project targeting the METTL3/METTL14 complex and established a robust discovery process as a platform for future projects. The company has also generated a library of high-quality compounds tailor-made for accelerated hit generation and hit-to-lead expansion against large parts of the epitranscriptomic target space. This library includes a collection of over 2,000 analogues covering over 80 distinct chemotypes that will be used to further accelerate Gotham’s drug discovery efforts as it expands its pipeline.The original link:https://www.pharmafocusasia.com/news/gotham-therapeutics-establishes-advanced-oncology-profiling-cascade-with-proqinase-to-progress-its-portfolio-of-epitranscriptomic-drug-candidates2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/510934/will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934

Gilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical DevelopmentTUESDAY, OCTOBER 29, 2019Gilead Sciences Inc. and Glympse Bio, Inc., today announced that the companies have entered into a strategic collaboration in nonalcoholic steatohepatitis (NASH) clinical development. Glympse Bio’s proprietary synthetic biomarkers – bioengineered to identify stage and progression of disease as well as early detection of treatment response – will be used to determine clinical trial participants’ stage of disease at initial screening and to determine responses to study treatment in Gilead’s NASH clinical program.“We are excited about the opportunity to partner with Glympse Bio to help inform our NASH development program,” said Mani Subramanian, MD, PhD Senior Vice President, Liver Diseases, Gilead Sciences. “By utilizing this innovative technology, we hope to better characterize this complex disease and improve our understanding of how our compounds impact disease progression.”Glympse Bio’s proprietary technology, Glympse Inside™, combines synthetic biomarkers with machine learning approaches to identify the stage and monitor progression of important, complex diseases such as cancer, fibrosis, inflammation, and infections, in real time.“We are very excited about partnering with Gilead, a leader in drug development, to help drive earlier and more favorable outcomes for patients,” said Caroline J Loew, President and CEO, Glympse Bio. “Gilead’s commitment to developing innovative medicines in areas of high unmet medical need aligns with our mission of transforming disease detection and measuring treatment response, all with the goal of helping improve the lives of patients.”information source:pharma focus AsiaThe original link:https:https:https://www.pharmafocusasia.com/news/gilead-and-glympse-bio-announce-strategic-collaboration-for-use-of-biomarker-technology-in-nash-clinical-development2019 Asia-pacific pharma IP Leader Summit:http://en.zenseegroup.com/p/510934/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934

HistoIndex Announces Global Partnerships To Expand AI-Based Digital Pathology PlatformMONDAY, OCTOBER 28, 2019HistoIndex announces the expansion of its AI-based digital pathology platform towards large-scale NASH preclinical programs for pharmaceutical and biotech companies to achieve quantifiable and reproducible data on therapeutic responses in NASH animal models, and to aid CROs as well as research agencies in validating new models mimicking the NASH disease.Published preclinical studies have demonstrated the use of HistoIndex's fully quantifiable Second Harmonic Generation (SHG) technology as a highly accurate stain-free method that can monitor the efficacy of various therapeutic agents, by quantifying more than 450 NASH-associated parameters in fibrosis, inflammation, ballooning and steatosis. The information of these NASH-associated parameters gathered from the entire liver tissue, provides comprehensive insights on the mechanism of action of the therapeutic agent.  As a drug discovery tool, HistoIndex's SHG-enabled digital pathology platform will allow pharmaceutical and biotech companies to select promising lead candidates for further optimization and make informed decisions in the management of their NASH drug development pipeline.In addition to ongoing NASH clinical trials, HistoIndex is currently involved in multiple preclinical studies, most of which are conducted by major pharmaceutical and biotech companies, medical universities, CROs and research agencies. Notably, HistoIndex has recently entered into a collaboration with the A*STAR's Genome Institute of Singapore (GIS) to validate their in vivo and in vitro NASH models based on Asian-centric clinical data. Says Professor Patrick Tan, Executive Director of the Genome Institute of Singapore (GIS), "At GIS, we conduct our preclinical studies on fatty liver involving data from animal models based on patient-derived transcriptomic data. This has a high translational potential as it helps us to pinpoint new therapeutic targets and their validation. Therefore, using a fully quantitative, reliable and objective pathological evaluation such as HistoIndex's AI-based digital pathology platform is essential to the success of our efforts in therapeutic target discovery."HistoIndex is also a partner with globally-renowned CRO, WuXi Apptec, in advancing their NASH preclinical programs with advanced R&D and smart imaging analysis capabilities. Published study data will be available for discussions during networking opportunities throughout AASLD's The Liver Meeting® in November 2019.  "We are very excited to extend our AI-based SHG platform to preclinical studies to help companies with drug discovery programs select promising lead candidates for further optimization and subsequent clinical development," says Dr Poon Thong Yuen, Chief Executive Officer of HistoIndex. "Our SHG image analysis platform has already been used to analyze the efficacy of a series of promising drug candidates for NASH within various animal models commonly-used by the industry, and we believe these preclinical partnerships will help drive the adoption of our platform significantly."information source:pharma focus AsiaThe original link:https:https://www.pharmafocusasia.com/news/histoindex-announces-global-partnerships-to-expand-ai-based-digital-pathology-platform2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/510934/will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934

AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR‑RD‑02 for the Treatment of Gaucher DiseaseFRIDAY, OCTOBER 25, 2019AVROBIO, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the Company’s investigational gene therapy, AVR-RD-02, for the treatment of Gaucher disease. AVR-RD-02 consists of the patient’s own hematopoietic stem cells, genetically modified to express glucocerebrosidase (GCase), the enzyme that is deficient in Gaucher disease. The Company is actively recruiting in Canada for its Phase 1/2 clinical trial of AVR-RD-02, which seeks to evaluate the safety and efficacy of the therapy in patients with Type 1 Gaucher disease.“Under the existing standard of care, patients with Gaucher disease are bound to a lifelong infusion schedule of enzyme replacement therapies, and still experience painful and progressive symptoms such as debilitating musculoskeletal pain and fatigue,” said Birgitte Volck, MD, PhD, President of Research and Development at AVROBIO. “Orphan-drug designation recognizes the unmet need of populations with rare diseases like Gaucher where AVROBIO strives to transform lives by addressing the underlying cause of the disease with a single dose of gene therapy.”Orphan-drug designation is granted by the FDA to drugs and biologics which are intended for the safe and effective treatment, diagnosis or prevention of rare diseases or conditions that affect fewer than 200,000 people in the United States. Orphan-drug designation provides certain incentives, which may include tax credits towards the cost of clinical trials and prescription drug user fee waivers.information source:pharma focus AsiaThe original link:https:https://www.pharmafocusasia.com/news/avrobio-receives-orphan-drug-designation-from-the-us-fda-for-avrrd02-for-the-treatment-of-gaucher-disease2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/510934/will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934

FRIDAY, OCTOBER 25, 2019AZTherapies, Inc., a biopharmaceutical company developing therapeutics to extend brain health, today announced the acquisition of Smith Therapeutics, a private biopharmaceutical company with a shared goal of targeting neuroinflammation to treat neurodegenerative disease. Smith Therapeutics’ Founder and Chief Executive Officer Philip Ashton-Rickardt, Ph.D., has joined the senior leadership team at AZTherapies as Senior Vice President of Immunology. Financial terms of the acquisition were not disclosed.Smith Therapeutics’ proprietary research platform focuses on the use of modified T cells to restore a healthy balance of inflammatory and regulatory cells in the brain. To date, Smith has successfully engineered immunosuppressive T regulatory (Treg) cells with Chimeric Antigen Receptors (CARs) targeting brain glial cells. Previous research has demonstrated the ability of Tregs to dampen microglial activity and reduce neuroinflammation in models of neurodegeneration, suggesting their potential utility in the treatment of diseases including Progressive Supranuclear Palsy (PSP), Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Amyotrophic Lateral Sclerosis (ALS), and others.“This acquisition represents a meaningful step forward for us as we continue to strengthen our leadership position in the development of therapies targeting neuroinflammation to stop or slow the progression of neurodegenerative diseases,” said David R. Elmaleh, Ph.D., Founder, CEO, and Chairman of AZTherapies. “We are excited to be working with Philip as we add this cutting-edge technology to our portfolio of innovative programs. An esteemed immunologist and inventor of the technology, Philip brings unparalleled expertise to the company and we look forward to advancing this CAR-Treg program further into IND-enabling studies and into clinical development as rapidly as possible.”Dr. Ashton-Rickardt commented on the acquisition and his appointment: “Our shared rationale of targeting neuroinflammation as the root cause of neurodegenerative disease makes this acquisition a great strategic fit for us. With AZTherapies’ expertise in drug development and clinical trial execution, we believe that together, we are well positioned to advance our CAR-Treg technology and fundamentally change neurodegenerative disease progression.”Prior to launching Smith Therapeutics in 2017, Dr. Ashton-Rickardt was Chair in Immunology at Imperial College London, Visiting Professor, Brigham and Women’s Hospital, Harvard Medical School, and Associate Professor in the Department of Pathology at the University of Chicago. His work has been recognized by his peers through the award of tenure from The University of Chicago and by his fellow citizens as a recipient of the Early Career Award for Scientists and Engineers from President Bill Clinton. He has published more than 65 peer-reviewed papers in more than 30 academic journals (including Cell, Science, Immunity, and Nature Immunology), has served as an editor for several academic journals, and has been a member of grant review boards globally. Dr. Ashton-Rickardt received a B.Sc. in Biochemistry from the University of London, King’s College with honors, a Ph.D. in Molecular Biology from the University of Edinburgh, and completed post-doctoral work at the University of Edinburgh and the Massachusetts Institute of Technology in Molecular Biology and Molecular Immunology, respectively.information source:pharma focus AsiaThe original link:https:https://www.pharmafocusasia.com/news/aztherapies-strengthens-neuroinflammation-targeted-pipeline-through-acquisition-of-smith-therapeutics2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/510934/will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934

About Us
Contact Us
Zensee_Daystar online